Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Singlera Reports Positive Results from Blood-based Diagnostic for Colorectal Cancer

publication date: Oct 18, 2018

Singlera Genomics, a San Diego-Shanghai diagnostics company, reported its ColonES blood-based colorectal cancer diagnostic showed high sensitivity and specificity in an early China test. In a 1,243 patient study, the ColonES device produced sensitivities of 93% for CRC and 88% for advanced adenomas, with a specificity of 99%. The device is aimed at early diagnosis. Its targeted next-gen sequencing is based on methylation haplotype signatures of circulating tumor methylated DNA (ctmDNA) in blood plasma. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital